Neurocognition, insight and medication nonadherence in schizophrenia: a structural equation modeling approach.

OBJECTIVE: The aim of this study was to examine the complex relationships among neurocognition, insight and nonadherence in patients with schizophrenia. METHODS: DESIGN: Cross-sectional study. INCLUSION CRITERIA: Diagnosis of schizophrenia according to the DSM-IV-TR criteria. DATA COLLECTION: Neuro...

Full description

Bibliographic Details
Main Authors: Laurent Boyer, Michel Cermolacce, Daniel Dassa, Jessica Fernandez, Mohamed Boucekine, Raphaelle Richieri, Florence Vaillant, Remy Dumas, Pascal Auquier, Christophe Lancon
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3483287?pdf=render
id doaj-2ce006b7270a4403a05c8f0d4d18206f
record_format Article
spelling doaj-2ce006b7270a4403a05c8f0d4d18206f2020-11-25T01:32:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-01710e4765510.1371/journal.pone.0047655Neurocognition, insight and medication nonadherence in schizophrenia: a structural equation modeling approach.Laurent BoyerMichel CermolacceDaniel DassaJessica FernandezMohamed BoucekineRaphaelle RichieriFlorence VaillantRemy DumasPascal AuquierChristophe LanconOBJECTIVE: The aim of this study was to examine the complex relationships among neurocognition, insight and nonadherence in patients with schizophrenia. METHODS: DESIGN: Cross-sectional study. INCLUSION CRITERIA: Diagnosis of schizophrenia according to the DSM-IV-TR criteria. DATA COLLECTION: Neurocognition was assessed using a global approach that addressed memory, attention, and executive functions; insight was analyzed using the multidimensional 'Scale to assess Unawareness of Mental Disorder;' and nonadherence was measured using the multidimensional 'Medication Adherence Rating Scale.' ANALYSIS: Structural equation modeling (SEM) was applied to examine the non-straightforward relationships among the following latent variables: neurocognition, 'awareness of positive symptoms' and 'negative symptoms', 'awareness of mental disorder' and nonadherence. RESULTS: One hundred and sixty-nine patients were enrolled. The final testing model showed good fit, with normed χ(2) = 1.67, RMSEA = 0.063, CFI = 0.94, and SRMR = 0.092. The SEM revealed significant associations between (1) neurocognition and 'awareness of symptoms,' (2) 'awareness of symptoms' and 'awareness of mental disorder' and (3) 'awareness of mental disorder' and nonadherence, mainly in the 'attitude toward taking medication' dimension. In contrast, there were no significant links between neurocognition and nonadherence, neurocognition and 'awareness of mental disorder,' and 'awareness of symptoms' and nonadherence. CONCLUSIONS: Our findings support the hypothesis that neurocognition influences 'awareness of symptoms,' which must be integrated into a higher level of insight (i.e., the 'awareness of mental disorder') to have an impact on nonadherence. These findings have important implications for the development of effective strategies to enhance medication adherence.http://europepmc.org/articles/PMC3483287?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Laurent Boyer
Michel Cermolacce
Daniel Dassa
Jessica Fernandez
Mohamed Boucekine
Raphaelle Richieri
Florence Vaillant
Remy Dumas
Pascal Auquier
Christophe Lancon
spellingShingle Laurent Boyer
Michel Cermolacce
Daniel Dassa
Jessica Fernandez
Mohamed Boucekine
Raphaelle Richieri
Florence Vaillant
Remy Dumas
Pascal Auquier
Christophe Lancon
Neurocognition, insight and medication nonadherence in schizophrenia: a structural equation modeling approach.
PLoS ONE
author_facet Laurent Boyer
Michel Cermolacce
Daniel Dassa
Jessica Fernandez
Mohamed Boucekine
Raphaelle Richieri
Florence Vaillant
Remy Dumas
Pascal Auquier
Christophe Lancon
author_sort Laurent Boyer
title Neurocognition, insight and medication nonadherence in schizophrenia: a structural equation modeling approach.
title_short Neurocognition, insight and medication nonadherence in schizophrenia: a structural equation modeling approach.
title_full Neurocognition, insight and medication nonadherence in schizophrenia: a structural equation modeling approach.
title_fullStr Neurocognition, insight and medication nonadherence in schizophrenia: a structural equation modeling approach.
title_full_unstemmed Neurocognition, insight and medication nonadherence in schizophrenia: a structural equation modeling approach.
title_sort neurocognition, insight and medication nonadherence in schizophrenia: a structural equation modeling approach.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2012-01-01
description OBJECTIVE: The aim of this study was to examine the complex relationships among neurocognition, insight and nonadherence in patients with schizophrenia. METHODS: DESIGN: Cross-sectional study. INCLUSION CRITERIA: Diagnosis of schizophrenia according to the DSM-IV-TR criteria. DATA COLLECTION: Neurocognition was assessed using a global approach that addressed memory, attention, and executive functions; insight was analyzed using the multidimensional 'Scale to assess Unawareness of Mental Disorder;' and nonadherence was measured using the multidimensional 'Medication Adherence Rating Scale.' ANALYSIS: Structural equation modeling (SEM) was applied to examine the non-straightforward relationships among the following latent variables: neurocognition, 'awareness of positive symptoms' and 'negative symptoms', 'awareness of mental disorder' and nonadherence. RESULTS: One hundred and sixty-nine patients were enrolled. The final testing model showed good fit, with normed χ(2) = 1.67, RMSEA = 0.063, CFI = 0.94, and SRMR = 0.092. The SEM revealed significant associations between (1) neurocognition and 'awareness of symptoms,' (2) 'awareness of symptoms' and 'awareness of mental disorder' and (3) 'awareness of mental disorder' and nonadherence, mainly in the 'attitude toward taking medication' dimension. In contrast, there were no significant links between neurocognition and nonadherence, neurocognition and 'awareness of mental disorder,' and 'awareness of symptoms' and nonadherence. CONCLUSIONS: Our findings support the hypothesis that neurocognition influences 'awareness of symptoms,' which must be integrated into a higher level of insight (i.e., the 'awareness of mental disorder') to have an impact on nonadherence. These findings have important implications for the development of effective strategies to enhance medication adherence.
url http://europepmc.org/articles/PMC3483287?pdf=render
work_keys_str_mv AT laurentboyer neurocognitioninsightandmedicationnonadherenceinschizophreniaastructuralequationmodelingapproach
AT michelcermolacce neurocognitioninsightandmedicationnonadherenceinschizophreniaastructuralequationmodelingapproach
AT danieldassa neurocognitioninsightandmedicationnonadherenceinschizophreniaastructuralequationmodelingapproach
AT jessicafernandez neurocognitioninsightandmedicationnonadherenceinschizophreniaastructuralequationmodelingapproach
AT mohamedboucekine neurocognitioninsightandmedicationnonadherenceinschizophreniaastructuralequationmodelingapproach
AT raphaellerichieri neurocognitioninsightandmedicationnonadherenceinschizophreniaastructuralequationmodelingapproach
AT florencevaillant neurocognitioninsightandmedicationnonadherenceinschizophreniaastructuralequationmodelingapproach
AT remydumas neurocognitioninsightandmedicationnonadherenceinschizophreniaastructuralequationmodelingapproach
AT pascalauquier neurocognitioninsightandmedicationnonadherenceinschizophreniaastructuralequationmodelingapproach
AT christophelancon neurocognitioninsightandmedicationnonadherenceinschizophreniaastructuralequationmodelingapproach
_version_ 1725083218886000640